Cegedim SA (EPA:ALCGM)
France · Delayed Price · Currency is EUR | Market Cap | 142.53M -0.5% |
| Revenue (ttm) | 649.17M -0.8% |
| Net Income | 9.40M |
| EPS | 0.68 |
| Shares Out | 13.73M |
| PE Ratio | 15.19 |
| Forward PE | 8.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,694 |
| Open | 10.58 |
| Previous Close | 10.38 |
| Day's Range | 10.38 - 10.58 |
| 52-Week Range | 8.50 - 15.30 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 15.50 (+49.33%) |
| Earnings Date | Sep 24, 2026 |
About Cegedim
Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare and B2B ecosystem in France, rest of Europe, the Middle East, Africa, and internationally. The company offers practice management, pharmacy management, healthcare center management, and MSP management software, as well as drug database and hosting of healthcare data for doctor, dentist, pharmacist, nurse, physiotherapist, podiatrist, speech therapist, midwife, and administrator health center; and drug distribution statistics, dig... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ALCGM stock is "Buy." The 12-month stock price target is €15.50, which is an increase of 49.33% from the latest price.
News
Cegedim Earnings Call Transcript: Q2 2026
H1 2026 revenue grew modestly, with strong Business Services and Data & Marketing offsetting declines in Healthcare Professionals and Cloud & Support. Management maintains guidance for over 2% like-for-like growth and higher EBIT, with e-invoicing reforms and Ségur subvention expected to boost H2 results.
Cegedim Earnings release: Q2 2026
Cegedim released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Cegedim Slides: Q2 2026
Cegedim has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Cegedim: Like-for-Like Revenues Fell 0.8% in the First Quarter of 2026
First-quarter revenues of €159.6 million, down €1.7 million or -1.0% on a reported basisNo impact on full-year outlook of like-for-like growth above 2% BOULOGNE-BILLANCOURT, FRANCE / ACCESS Newswir...
Cegedim Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined slightly due to tough comparisons in cloud and support, but growth was seen in business services and international health segments. Full-year guidance remains for over 2% like-for-like growth, with e-business expected to accelerate in 2027.
Cegedim Earnings release: Q1 2026
Cegedim released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Cegedim Slides: Q1 2026
Cegedim has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Cegedim: Release of its 2025 Universal Registration Document
BOULOGNE-BILLANCOURT, FR / ACCESS Newswire / April 17, 2026 / Cegedim, an innovative technology and services company, announces that its 2025 Universal Registration Document (in French) has been publi...
Cegedim Earnings Call Transcript: H2 2025
Adjusted operating income rose 25% to €49.4M with margin up to 7.6%, while net income swung to €8.3M from a loss last year. Strong cost control and tax reimbursement drove results, with net debt reduced by 25%.
Cegedim Earnings release: H2 2025
Cegedim released its H2 2025 earnings on March 26, 2026, summarizing the period's financial results.
Cegedim Slides: H2 2025
Cegedim has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.
Cegedim Annual report: H2 2025
Cegedim has published its H2 2025 annual report on March 26, 2026.
Cegedim Earnings Call Transcript: Q4 2025
Full year 2025 revenue was €649.2M, up 1.1% like-for-like, with strong HR, e-business, and insurance segments offset by pharmacy reorganization and deconsolidation impacts. Adjusted operating income is targeted to grow at least 15%, with 2026 revenue growth expected at 2–4%.
Cegedim Earnings release: Q4 2025
Cegedim released its Q4 2025 earnings on January 29, 2026, summarizing the period's financial results.
Cegedim Slides: Q4 2025
Cegedim has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 29, 2026.
Cegedim Earnings Call Transcript: Q3 2025
Q3 revenue declined 2% reported but grew 0.5% like-for-like, with nine-month growth at 2.1%. Full-year guidance is maintained, with adjusted operating income and EBIT expected to improve, driven by strong cloud, HR software, and insurance segments.
Cegedim Earnings release: Q3 2025
Cegedim released its Q3 2025 earnings on October 23, 2025, summarizing the period's financial results.
Cegedim Slides: Q3 2025
Cegedim has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 23, 2025.
Cegedim Earnings Call Transcript: H1 2025
Revenue grew 1.1% to EUR 322.5 million in H1 2025, with adjusted operating income up 78% and strong cash flow reducing net debt by 15%. Restructuring in the pharmacy segment and the sale of In Practice Systems impacted non-recurring items, while all divisions reported positive adjusted operating income.
Cegedim Quarterly report: H1 2025
Cegedim has published its H1 2025 quarterly earnings report on September 25, 2025.
Cegedim Earnings release: H1 2025
Cegedim released its H1 2025 earnings on September 25, 2025, summarizing the period's financial results.
Cegedim Slides: H1 2025
Cegedim has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 25, 2025.
Cegedim's profitability improving as expected in H1 2025
PRESS RELEASE First-half financial information as of June 30, 2025 IFRS - Regulated information - Not audited Cegedim's profitability improving as expected Revenue up 1.1% as reported and 2.8% LFL to ...